97 related articles for article (PubMed ID: 11251179)
41. Rare-type mutations of MMAC1 tumor suppressor gene in human glioma cell lines and their tumors of origin.
Zhang SJ; Endo S; Ichikawa T; Yoshimura J; Onda K; Tanaka R; Washiyama K; Kumanishi T
Jpn J Cancer Res; 1999 Sep; 90(9):934-41. PubMed ID: 10551321
[TBL] [Abstract][Full Text] [Related]
42. Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Maxwell GL; Risinger JI; Tong B; Shaw H; Barrett JC; Berchuck A; Futreal PA
Gynecol Oncol; 1998 Jul; 70(1):13-6. PubMed ID: 9698466
[TBL] [Abstract][Full Text] [Related]
43. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.
Zhou XP; Loukola A; Salovaara R; Nystrom-Lahti M; Peltomäki P; de la Chapelle A; Aaltonen LA; Eng C
Am J Pathol; 2002 Aug; 161(2):439-47. PubMed ID: 12163369
[TBL] [Abstract][Full Text] [Related]
44. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
45. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.
Rhei E; Kang L; Bogomolniy F; Federici MG; Borgen PI; Boyd J
Cancer Res; 1997 Sep; 57(17):3657-9. PubMed ID: 9288766
[TBL] [Abstract][Full Text] [Related]
46. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.
Marsh DJ; Coulon V; Lunetta KL; Rocca-Serra P; Dahia PL; Zheng Z; Liaw D; Caron S; Duboué B; Lin AY; Richardson AL; Bonnetblanc JM; Bressieux JM; Cabarrot-Moreau A; Chompret A; Demange L; Eeles RA; Yahanda AM; Fearon ER; Fricker JP; Gorlin RJ; Hodgson SV; Huson S; Lacombe D; Eng C
Hum Mol Genet; 1998 Mar; 7(3):507-15. PubMed ID: 9467011
[TBL] [Abstract][Full Text] [Related]
47. Expression status and mutational analysis of the PTEN and P13K subunit genes in ovarian granulosa cell tumors.
Bittinger S; Alexiadis M; Fuller PJ
Int J Gynecol Cancer; 2009 Apr; 19(3):339-42. PubMed ID: 19407556
[TBL] [Abstract][Full Text] [Related]
48. Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas.
Kurose K; Zhou XP; Araki T; Eng C
Genes Chromosomes Cancer; 2000 Oct; 29(2):166-72. PubMed ID: 10959096
[TBL] [Abstract][Full Text] [Related]
49. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Teng DH; Hu R; Lin H; Davis T; Iliev D; Frye C; Swedlund B; Hansen KL; Vinson VL; Gumpper KL; Ellis L; El-Naggar A; Frazier M; Jasser S; Langford LA; Lee J; Mills GB; Pershouse MA; Pollack RE; Tornos C; Troncoso P; Yung WK; Fujii G; Berson A; Steck PA
Cancer Res; 1997 Dec; 57(23):5221-5. PubMed ID: 9393738
[TBL] [Abstract][Full Text] [Related]
50. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.
Manzano RG; Montuenga LM; Dayton M; Dent P; Kinoshita I; Vicent S; Gardner GJ; Nguyen P; Choi YH; Trepel J; Auersperg N; Birrer MJ
Oncogene; 2002 Jun; 21(28):4435-47. PubMed ID: 12080474
[TBL] [Abstract][Full Text] [Related]
51. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.
Han SY; Kato H; Kato S; Suzuki T; Shibata H; Ishii S; Shiiba K; Matsuno S; Kanamaru R; Ishioka C
Cancer Res; 2000 Jun; 60(12):3147-51. PubMed ID: 10866302
[TBL] [Abstract][Full Text] [Related]
52. Chromosomal localization of human, rat, and mouse protein phosphatase type 1 beta catalytic subunit genes (PPP1CB) by fluorescence in situ hybridization.
Saadat M; Kakinoki Y; Mizuno Y; Kikuchi K; Yoshida MC
Jpn J Genet; 1994 Dec; 69(6):697-700. PubMed ID: 7857673
[TBL] [Abstract][Full Text] [Related]
53. Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis.
Luo W; Xu C; Ayello J; Dela Cruz F; Rosenblum JM; Lessnick SL; Cairo MS
Oncogene; 2018 Feb; 37(6):798-809. PubMed ID: 29059150
[TBL] [Abstract][Full Text] [Related]
54. Assay for three-way interaction of protein phosphatase-1 (Glc7) with regulatory subunits plus phosphatase inhibitor-2.
Eto M; Brautigan DL
Methods Mol Biol; 2007; 365():197-208. PubMed ID: 17200563
[TBL] [Abstract][Full Text] [Related]
55. PTEN/MMAC1 mutations in hepatocellular carcinomas.
Yao YJ; Ping XL; Zhang H; Chen FF; Lee PK; Ahsan H; Chen CJ; Lee PH; Peacocke M; Santella RM; Tsou HC
Oncogene; 1999 May; 18(20):3181-5. PubMed ID: 10340391
[TBL] [Abstract][Full Text] [Related]
56. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
57. Translocation of protein phosphatase 1 catalytic subunits during 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL-60 cells.
Omay SB; Ogasawara H; Toyoda H; Nakai K; Shima H; Nagao M; Mumby MC; Shiku H; Nishikawa M
Cancer Res; 1995 Feb; 55(4):774-80. PubMed ID: 7850788
[TBL] [Abstract][Full Text] [Related]
58. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.
Koul D; Jasser SA; Lu Y; Davies MA; Shen R; Shi Y; Mills GB; Yung WK
Oncogene; 2002 Apr; 21(15):2357-64. PubMed ID: 11948419
[TBL] [Abstract][Full Text] [Related]
59. Protein tyrosine kinase and phosphatase expression profiling in human cancers.
Lin WC
Methods Mol Biol; 2003; 218():113-25. PubMed ID: 12616716
[TBL] [Abstract][Full Text] [Related]
60. Somatic mutation of PTEN in bladder carcinoma.
Aveyard JS; Skilleter A; Habuchi T; Knowles MA
Br J Cancer; 1999 May; 80(5-6):904-8. PubMed ID: 10360673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
